Narcolepsy Treatment Market Development Trends & Competitive Analysis by Research Report Forecast 2017-2025

Narcolepsy Treatment Market:Overview

Narcolepsy is a rare condition, which is often under diagnosed. The condition is characterized by excessive sleepiness, hallucination, sleep paralysis, excessive day time sleepiness, cataplexy, and automatic behaviors. Narcolepsy is caused due to lack of brain chemical known as orexin which regulates sleep. Several other factors can trigger narcolepsy such as menopause and puberty. The condition is rare and is estimated to affect more than 1 in 2000 people in the U.S. The condition does not have any cure, but drugs can improve the symptoms and bring about changes in lifestyle.

Report Overview:

https://www.transparencymarketresearch.com/narcolepsy-treatment-market.html

The global narcolepsy treatment market is expect to expand at a moderate CAGR during the forecast period. Increase in awareness about sleep disorders, rise in prevalence of these disorders due to unhealthy lifestyle, and surge in stress levels are the major factors anticipated to drive the global narcolepsy treatment market during the forecast period.

Increase in demand for advanced therapies for sleeping disorders, extensive efforts of government and non-governmental organizations for spreading awareness about the disease, rise in R&D activities to find a cure for narcolepsy are the other factors expected to propel the global market. Moreover, rise in health care expenditure and reimbursement policies fuel the growth of the global narcolepsy treatment market during the forecast period. However, lack of awareness among patients and health care providers about the disease in developing countries are likely to restrain the global narcolepsy market during the forecast period.

Request For Custom Research:

https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=39383

The global narcolepsy treatment market can be segmented based on drug class, narcolepsy type, end-user, and region. In terms of drug class, the market can be classified into vasopressors, CNS stimulants, decongestants, serotonin reuptake inhibitors, and miscellaneous.

Sodium Oxybate in the miscellaneous segment is expected to account for a significant share of the global market during the forecast period due to favorable reimbursement policies. Based on narcolepsy type, the global narcolepsy treatment market can be bifurcated into narcolepsy type 1 and 2. In terms of end-user, the market can be divided into drug stores, retail pharmacies, and e-commerce.

Request for covid19 Impact Analysis:

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=39383

The global narcolepsy treatment market is expected to grow at a significant pace across all regions. Geographically, the global market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the global market in 2016 and is expected to continue its dominance during the forecast period. Increase in awareness towards narcolepsy treatment, prevalence of unhealthy lifestyle etc.

are few of the major factor driving the growth of market in the region. Furthermore, advanced technology, rise in awareness among people about diagnosis of the disease, and high health care expenditure boost the growth of the narcolepsy treatment market in North America. Europe is also anticipated to account for a significant share of the global market due to increase in R&D activities and well-established health care infrastructure.

The market in Asia Pacific is anticipated to expand at a faster growth rate during the forecast period. Asia Pacific is the most lucrative market due to rise in disposable income, adoption of health care solutions for better standard of life, rise in awareness about health, prevalence of lifestyle related diseases, surge in investment in pharmaceuticals and biotechnology sectors, and high prevalence of narcolepsy in countries such as Japan.

Key players have adopted strategies such as extensive R&D, mergers, cost-effective drugs, collaborative partnerships, and approval from regulatory authorities to capture leadership position in the global narcolepsy treatment market. For instance, Jazz Pharmaceuticals' Xyrem is the only U.S.

FDA-approved drug used for cataplexy. Prominent players operating in the global narcolepsy treatment market are Jazz Pharmaceuticals plc, Bioprojet, Arena Pharmaceuticals, Inc., and Graymark Healthcare, Inc., among others.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/plasma-protein-therapeutics-market-to-advance-at-cagr-of-7-0-during-20192027--tmr-study-301479920.html

https://www.prnewswire.com/news-releases/c-arms-market-is-projected-to-expand-at-cagr-of-3-4-during-the-forecast-period-says-tmr-study-301483280.html

Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time.

For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.